🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. CARBOPLATIN, CISPLATIN, PEGFILGRASTIM, PEMETREXED, BL-B01D1

    Bristol-Myers Squibb Australia Pty Ltd

    EGFR-mutated Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. CARBOPLATIN, CISPLATIN, PEMBROLIZUMAB, PEMETREXED, DS-8201a, PEMETREXED

    AstraZeneca AB

    Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations

    phase 3 small molecule active

    1 trial

  3. CARBOPLATIN, CISPLATIN, PEMETREXED, CARBOPLATIN, PEMETREXED, OSIMERTINIB, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, CARBOPLATIN, PEMETREXED

    AbbVie Deutschland GmbH & Co. KG

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  5. CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02

    Hoffmann-La Roche

    RET fusion−positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. CARBOPLATIN, PACLITAXEL, DOCETAXEL, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  7. CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride

    Sarepta Therapeutics

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial

  8. CAZ-AVI

    Pfizer

    Complicated Intra-Abdominal Infection

    phase 3 small molecule completed

    1 trial

  9. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Treatment Resistant Psychosis

    phase 3 small molecule active

    1 trial

  10. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Psychosis

    phase 3 small molecule active

    1 trial

  11. CBP-201

    S.L

    Atopic Dermatitis

    phase 3 small molecule active

    2 trials

  12. CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 3 small molecule active

    1 trial

  13. CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib

    Pharming Technologies B.V.

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 3 small molecule active

    1 trial

  14. CEFTAZIDIME, PIPERACILLIN, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE, CEFTAZIDIME, CEFEPIME , CEFEPIME, MEROPENEM , TAZOBACTAM, TAZOBACTAM, MEROPENEM, AMIKACIN , AMIKACIN, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR , AVIBACTAM, CEFTAZIDIME

    Pari Pharma GmbH

    antibiotic therapy in Sepsis

    phase 3 small molecule active

    1 trial

  15. CEFTRIAXONE , CEFIXIME , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMIKACIN

    Pari Pharma GmbH

    acute pyelonephritis (AP) in children

    phase 3 small molecule active

    1 trial

  16. CEFTRIAXONE , TEMOCILLIN , Negaban 2 g poudre pour solution injectable/pour perfusion

    Pari Pharma GmbH

    Neisseria gonorrhoeae Infections

    phase 3 small molecule active

    1 trial

  17. CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable, Clarithromycine EG 500 mg comprimés pelliculés, MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable

    Pari Pharma GmbH

    Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes

    phase 3 small molecule active

    1 trial

  18. CEFTRIAXONE, AMOXICILLIN, AZITHROMYCIN

    Pari Pharma GmbH

    Population of study participants Pregnant women with PPROM at 22 to 33 weeks’ gestation

    phase 3 small molecule active

    1 trial

  19. CEP-10953 (Armodafinil)

    Teva Pharma GmbH

    Narcolepsy

    phase 3 small molecule completed

    1 trial

  20. CEP-1347 10mg

    Teva Pharma GmbH

    Parkinson Disease

    phase 3 small molecule terminated

    1 trial

  21. CEP-33457

    Teva Pharma GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    2 trials

  22. CETUXIMAB

    Disc Medicine

    oral squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  23. CF101

    Can-Fite BioPharma

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    2 trials

  24. CF101

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources